Technical Analysis for KZIA - Kazia Therapeutics Limited - American Depositary Shares

Grade Last Price % Change Price Change
grade F 3.0363 4.34% 0.13
KZIA closed up 4.34 percent on Friday, May 24, 2019, on 20 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Flat
See historical KZIA trend table...

Date Alert Name Type % Chg
180 Bearish Setup Bearish Swing Setup 4.34%
Doji - Bullish? Reversal 4.34%
Gapped Down Weakness 4.34%
Narrow Range Bar Range Contraction -2.59%
Gapped Up Strength -2.59%
Narrow Range Bar Range Contraction -2.05%
Gapped Down Weakness -2.05%
Narrow Range Bar Range Contraction -3.30%
NR7 Range Contraction -3.30%
NR7-2 Range Contraction -3.30%

Older signals for KZIA ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Kazia Therapeutics Limited, formerly Novogen Limited, is an oncology biotechnology company, which is focused on developing cancer treatments. The Company is primarily engaged in pharmaceutical research and development. It has two drug technology platforms (the Superbenzopyran (SBP) technology and Anti-tropomyosin (ATM)) yielding various drug candidates across a range of oncology indications. The Company's product candidates include Cantrixil (TRX-E-002-1), Anisina (ATM-3507) and Trilexium (TRX-E-009-1). The Company's target indication for Cantrixil is ovarian cancer, and Diffuse Intrinsic Pontine Glioma (DIPG) for Trilexium. The initial target pediatric indication for Anisina is neuroblastoma. Cantrixil is the lead development candidate arising from its SBP technology. Anisina is an approach to chemotherapy that targets the cancer cells' actin cytoskeleton. Trilexium (TRX-E-009-1) is its second lead SBP drug candidate.
Biotechnology Cancer ATM Organ Systems Chemotherapy Ovarian Cancer Neuroblastoma Glioma Pharmaceutical Research Diffuse Intrinsic Pontine Glioma
Is KZIA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 5.648
52 Week Low 2.04
Average Volume 4,005
200-Day Moving Average 3.1589
50-Day Moving Average 3.4055
20-Day Moving Average 3.1803
10-Day Moving Average 3.0438
Average True Range 0.1828
ADX 17.06
+DI 19.8787
-DI 28.4608
Chandelier Exit (Long, 3 ATRs ) 3.1916
Chandelier Exit (Short, 3 ATRs ) 3.4184
Upper Bollinger Band 3.5473
Lower Bollinger Band 2.8133
Percent B (%b) 0.3
BandWidth 23.079584
MACD Line -0.1045
MACD Signal Line -0.0978
MACD Histogram -0.0067
Fundamentals Value
Market Cap 14.67 Million
Num Shares 4.83 Million
EPS -1.80
Price-to-Earnings (P/E) Ratio -1.69
Price-to-Sales 2.05
Price-to-Book 0.71
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.28
Resistance 3 (R3) 3.27 3.17 3.24
Resistance 2 (R2) 3.17 3.11 3.18 3.23
Resistance 1 (R1) 3.10 3.07 3.14 3.12 3.21
Pivot Point 3.01 3.01 3.02 3.01 3.01
Support 1 (S1) 2.94 2.94 2.97 2.95 2.86
Support 2 (S2) 2.84 2.91 2.85 2.85
Support 3 (S3) 2.78 2.84 2.83
Support 4 (S4) 2.79